Soticlestat
Phase 3Small molecule
TakedaSoticlestat is one of 49 small molecule programs targeting Lennox-Gastaut syndrome. It is currently in Phase 3.
4
Indications
13
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Complex Regional Pain Syndrome
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Suboxone
IIndivior Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Low-Dose Naltrexone
SStanford University
Approved
Duragesic
CCephalon
Phase 3
Zometa
PfizerPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Zarontin
PParkedale
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Adult4 trials
Lennox-Gastaut syndrome3 trials
Complex Regional Pain Syndrome1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Soticlestat. EMBL-EBI & Wellcome Sanger Institute.
- [4]